NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
12/18/2025
Back to search
Official data from USPTO
XTANDI SUPPORT SOLUTIONS (ENZALUTAMIDE) 40 MG CAPSULES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
01/06/2026
Trademark type
Combined
Nice classes
35, 36, 44
Filing date
02/03/2015
Registration date
10/20/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/18/2025
Last transaction
01/06/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
09/10/2014
First use in commerce
09/10/2014
Drawing code
3
Owner type
16
Owner location
Northbrook, IL
Examiner
SAITO, KIM
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the design of a curved band surrounded by three incomplete circles to the left of the stylized wording "XTANDI (ENZALUTAMIDE) 40 MG CAPSULES". Two vertical curved lines make up the letters "SS" next to the stylized wording "SUPPORT SOLUTIONS".
Holders and representatives
Holders
Astellas US LLC
Representatives
Christopher Bolinger Astellas US LLC
Technical classification
Nice Classes
Class 35Class 36Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
business administration of health reimbursement arrangements; providing information regarding access to enrollment and reimbursement programs for the purchase of medications
Class 36
providing information to health care providers and patients about patient reimbursement and insurance coverage for pharmaceuticals; providing information on government and other third parties' financial assistance programs to assist in the purchase of medications; financial administration of health reimbursement arrangements
Class 44
providing health care information to patients by telephone and the Internet regarding management of medical treatments
Publications
History of USPTO decisions and trademark events.
46 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
12/18/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
12/18/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/18/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
09/10/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/07/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/07/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/07/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/07/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/07/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/20/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
07/09/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/09/2024
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/30/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/30/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/30/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/24/2021
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/23/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/23/2021
E815
TEAS SECTION 8 & 15 RECEIVED
09/22/2021
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/20/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/20/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/04/2015
PUBO
PUBLISHED FOR OPPOSITION
08/04/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/15/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/26/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/24/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
06/24/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/24/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
06/24/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/24/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/23/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/23/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/23/2015
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
03/17/2015
ALIE
ASSIGNED TO LIE
03/16/2015
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
03/16/2015
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
03/16/2015
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
03/16/2015
DOCK
ASSIGNED TO EXAMINER
03/04/2015
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/13/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2015
NWAP
NEW APPLICATION ENTERED
02/06/2015
Continuous trademark protection
Get notified about every new filing that threatens XTANDI SUPPORT SOLUTIONS (ENZALUTAMIDE) 40 MG CAPSULES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.